#liver cancer

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

Older people with hepatitis C have some disadvantages compared with younger people.

This is particularly true among men older than 50, who warrant greater monitoring.

This holds true even for those with highly severe liver disease.

Compared with the standard treatment, this new method also appears to be safer—but it doesn’t offer a longer life.

The survival benefits over a placebo are modest, however.

Researchers retooled the non-alcoholic steatohepatitis treatment FGF19 to yield a variant dubbed NGM282.

But curing hepatitis C does lower the risk of liver cancer.

This elevated risk, seen among a group largely uncured of hep C, remained even when factoring out liver cancer.

These benefits include reduction in both liver- and non-liver-related health outcomes and causes of death.

A high hep C burden is likely to blame for high rates among boomers, although new treatments may slow these rates in coming years.

Hepatitis C is curable, but if you have cirrhosis, you are at risk for liver cancer. A look at new research along with how you can help.

About 3 percent of nearly 3,000 cirrhotic HIV/HCV-positive men in major registries developed liver cancer in a recent analysis.

A look at the latest research addressing hepatitis C treatment and liver cancer risk